Indeed, CD34+CCR2+ flow cytometry detection in peripheral blood and/or bone marrow aspirates demonstrated a very good diagnostic performance in discriminating pre-PMF vs. true ET patients, as well as pre-PMF vs. overt-PMF patients, and also for patient longitudinal follow-up. The gene discussed is CCR2; the disease is essential thrombocythemia.